Indication

Ventavis is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominately patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).

• About Ventavis

•      Indications

•      Clinical Trials

•      Efficacy

•           Clinical Improvement

•           Improved Exercise
            Capacity

•           Functional Class
            Improvement

•           Improved
            Hemodynamics

•      Safety Profile

•      FAQs

•      Ventavis Support

• About the I-neb AAD
  System

• Services for Your Patients

• Resources

• Prescribing Information

• For Patients and
  Caregivers

Dosage and Administration

• Ventavis^® (iloprost) Inhalation Solution should be taken 6 to 9 times per day (no more than once every 2 hours).¹
• Dosing recommended during waking hours (90% of clinical trial patients never inhaled Ventavis during sleeping hours).¹
• Ventavis is intended for inhalation administration via a breath-actuated pulmonary drug delivery system: the I-neb AAD System.
• The first inhaled dose should be 2.5 mcg (as delivered at the mouthpiece).¹
  • If the 2.5-mcg dose is well tolerated, dosing should be increased to 5.0 mcg and maintained.
  • If the 5.0-mcg dose is not tolerated, dosing should be reduced to and maintained at 2.5 mcg.
  • The 20 mcg/mL concentration is intended for patients who are maintained at the 5 mcg dose and who have repeatedly experienced extended treatment times which could result in incomplete dosing. Ventavis 10 mcg/mL ampules are still available. Ventavis should be taken 6 to 9 times daily, at least 2 hours apart.¹
    • Higher concentration—50% reduction in inhaled volume
    • Shorter treatment times
    • Helps maintain patient compliance
    • Treatment convenience
• For each inhalation treatment, follow what is described in the full Prescribing Information.
  • After each inhalation session, any solution remaining in the I-neb AAD System medication chamber should be discarded.
  • Use of remaining solution will result in unpredictable dosing.

IMPORTANT SAFETY INFORMATION

Hypotension leading to syncope has been observed; Ventavis should therefore not be initiated in patients with systolic blood pressure less than 85 mmHG. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension. Ventavis inhalation may cause brochospasm and patients with a history of hyperreactive airway disease may be more sensitive. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Ventavis has the potential to increase risk of bleeding, particularly in patients maintained on anticoagulants.

Please see full Prescribing Information